Leadership Team

Dr Robin Bannister

CEO, Co-founder

Robin has over 30 years in Biopharma R&D commercialisation with proven success as a drug developer & entrepreneur, illustrated by the multiple marketed products and successful exits (e.g. Seebri, Arakis) spanning his career to date. Robin has particular scientific expertise in novel biology exploitation via the development of high–value, low-risk products. Robin is an Executive Director of TRx Biosciences Limited.

John Brew

CSO, Co-founder

With over 20 years experience in biopharma product development, John has progressed numerous R&D programmes from concept to market (e.g. Flarin™️). John has developed deep experience in non-clinical & clinical development & regulatory affairs. His scientific expertise spans biology, toxicology, pharmacology, pharmacokinetics & pharmaceutics. John is an Executive Director of TRx Biosciences Limited.

Dr Dan Gooding

CBO, Co-founder
Dan brings >20 years experience in biopharma technology development, commercialisation, entrepreneurship & business development. As founding CEO of Nuformix, Dan oversaw seed round to IPO securing >20x for founder investors. completing multiple out-licensing & financing transactions whilst transitioning NFX from technology development to product development. Dan is an Executive Director of TRx Biosciences Limited.


Dr Andy Richards CBE

Dr Andy Richards CBE has an established track record in founding and scaling up innovative Biotech and Healthtech companies in the UK. He is currently Chairman of Arecor, Congenica, Abcodia and the Babraham Research Campus and is a Director of Ieso Digital Health, Cancer Research Technology (commercial board of CR-UK) and Owlstone Medical. Since 1999 he has founded, invested in and helped to scale more than 25 innovative ventures including companies such as Vectura, Arakis, Cambridge Biotechnology Ltd and Geneservice. Andy is also a founder member of the Cambridge Angels and a director of The Scale Up Institute.

Professor Chris Frampton

Chris is the author and co-author of over 40 patents and over 150 peer-reviewed research publications and in April 2015 was named in the Global Top 100 Most Influential Medicine Makers Power List. Chris has extensive industry experience, co-founding Nuformix plc and Pharmorphix Ltd. He was based at Roche Discovery Welwyn for nine years, before moving to the position of Director of Strategic Marketing at Bruker AXS and is currently the CEO of Rbar3 Ltd. Chris has acted as an expert witness in a number of high-profile legal cases in both the US and the UK and currently holds the posts of visiting Professor of Chemical Engineering, Kings College London and visiting Professor of Structural Chemistry at Brunel University.